Scientific Hub of Applied Research in Emerging Medical science & technology (SHAREme)

SHARMEme |Vol.4 | Issue 4| Oct - Dec -2025

https://shareme.joinjet.org/

ISSN: 2583-3162

DOI : https://doi.org/10.61096/SHAREme.v4.iss4.2025.142-152

Review

HPLC in the Era of Biopharma: Advances in Column Chemistry, Automation and Data Analytics

Nagajyothi Bhavanam*

Senior Scientist, Analytical research and development, Cambrex Highpoint ,4170 Mendenhall Oaks Pkwy,North Carolina 27265 USA

*Author for Correspondence: Nagajyothi Bhavanam
Email: bhavanamnagajyothi25@gmail.com

Published on: 26 Oct 2025

Published by:
Futuristic Publications

Abstract

High-performance liquid chromatography (HPLC) remains the cornerstone of analytical characterization in the biopharmaceutical industry, despite the proliferation of newer orthogonal and hyphenated techniques. The rapid expansion of biologics including monoclonal antibodies, peptides, oligonucleotides, viral vectors, and antibody–drug conjugates has necessitated substantial advances in chromatographic science. Innovations in column chemistry, encompassing superficially porous particles, hybrid organic–silica materials, and monolithic supports, have enhanced the resolution, sensitivity, and speed of biomolecule separations. Parallel to these material advancements, the integration of automation, artificial intelligence (AI), and advanced data analytics has transformed chromatographic workflows into highly intelligent, self-optimizing systems. Modern HPLC instruments are now embedded within digital ecosystems that comply with regulatory expectations, promote sustainability, and align with the principles of Quality-by-Design (QbD) and Process Analytical Technology (PAT). This review provides an in-depth analysis of the evolution of HPLC in the biopharmaceutical era, focusing on developments in column design, mobile-phase optimization, detection systems, and digital transformation. Furthermore, it discusses how emerging paradigms such as green chromatography, AI-driven decision support, and continuous analytics are redefining the future of pharmaceutical quality assurance. By integrating scientific innovation with data-driven intelligence, HPLC continues to serve as an indispensable analytical platform in biopharmaceutical discovery, process development, and regulatory compliance.

Keywords: HPLC, biopharmaceutical analysis, column chemistry, automation, data analytics

1.0 INTRODUCTION

High-performance liquid chromatography (HPLC) has long served as the analytical backbone of pharmaceutical quality control, yet its role has evolved dramatically with the advent of complex biopharmaceutical products. The shift from small molecules to large, structurally diverse biologics including monoclonal antibodies (mAbs), recombinant proteins, nucleic acid therapeutics, and viral vectors has placed new demands on chromatographic resolution, sensitivity, and robustness. Traditional reversed-phase and ion-exchange modes, originally designed for small molecules, often fail to adequately resolve macromolecular heterogeneity or post-translational modifications. Consequently, a new era of HPLC innovation has emerged, encompassing both hardware and data-centric enhancements that collectively redefine analytical performance [1,2]. Modern HPLC platforms now integrate hybrid stationary phases, enhanced detector arrays, ultra-high-pressure operation, and automated workflows governed by artificial intelligence (AI). The convergence of chromatographic science with data analytics and computational modeling has produced "digital chromatography" a paradigm wherein algorithms optimize parameters such as flow rate, gradient, and mobile-phase composition in real time. Furthermore, regulatory frameworks emphasizing Quality-by-Design (QbD) and Process Analytical Technology (PAT) have encouraged the application of robust, validated chromatographic methods for real-time process monitoring [3].

The growing complexity of biologics also necessitates orthogonal characterization strategies, wherein HPLC is combined with mass spectrometry (LC–MS), capillary electrophoresis (CE), and spectroscopy to provide multi-dimensional insights. Simultaneously, sustainability considerations have fostered the emergence of green HPLC practices, including solvent minimization, recyclable materials, and energy-efficient instrumentation. These multifaceted developments position HPLC not merely as an analytical tool, but as a critical enabler of digital biopharmaceutical manufacturing in the era of Industry 5.0 [4,5].

1.1 The Expanding Role of HPLC in Biopharmaceutical Analysis

The analytical landscape of biopharmaceuticals is distinguished by its molecular diversity and structural complexity, which demand highly specific and robust chromatographic solutions. HPLC has become indispensable for the separation, identification, and quantification of biomolecules ranging from recombinant peptides and therapeutic proteins to biosimilars and oligonucleotide-based drugs. In biopharma pipelines, HPLC supports all stages from upstream cell culture monitoring to downstream purification validation and final quality control [6,7]. For protein and mAb analysis, reversed-phase HPLC (RP-HPLC) is routinely used to assess purity, aggregation, and degradation, while ion-exchange chromatography (IEX) resolves charge variants arising from glycosylation or deamidation. Size-exclusion chromatography (SEC) enables rapid determination of aggregate content and molecular size distribution. Similarly, hydrophobic interaction chromatography (HIC) offers valuable insights into protein folding, hydrophobic patches, and stability. In nucleic acid therapeutics, such as antisense oligonucleotides and mRNA constructs, ion-pair reversed-phase and anion-exchange HPLC are employed to monitor synthesis fidelity and degradation pathways [8].

Moreover, HPLC acts synergistically with LC–MS to enhance molecular specificity, especially for structural elucidation, post-translational modification mapping, and impurity profiling. Capillary electrophoresis (CE) and HPLC complement each other in charge variant and size heterogeneity assessments. The increasing reliance on biosimilars and biobetters further underscores the importance of precise chromatographic characterization to demonstrate structural and functional equivalence [9]. As regulatory agencies such as the FDA and EMA mandate extensive analytical comparability data, HPLC remains the reference standard for quantifying and validating product integrity in the biopharmaceutical sector [10].

1.2 Evolution of Column Chemistry: Superficially Porous, Hybrid, and Monolithic Phases

Column technology lies at the heart of chromatographic innovation, directly influencing efficiency, resolution, and throughput. Over the past decade, significant advances in stationary-phase materials have transformed HPLC performance, particularly for the analysis of high-molecular-weight and labile biomolecules. Superficially porous particles (SPPs), also known as core–shell or superficially porous materials, consist of a solid, impermeable core surrounded by a thin porous shell. This architecture reduces diffusion paths, minimizes band broadening, and enhances mass transfer kinetics, enabling high-efficiency separations even under moderate backpressure conditions [11,12]. Hybrid organic–inorganic silica phases have gained prominence due to their superior mechanical and chemical stability, extending the pH operating window and reducing silanol activity. Materials such as ethylene-bridged hybrid (BEH) and bridged-ethyl hybrid phases have improved column lifetimes and reproducibility under harsh mobile-phase conditions. These hybrid phases are particularly beneficial for the analysis of peptides and oligonucleotides, where acidic and basic environments can degrade traditional silica supports [13].

Monolithic columns, composed of a continuous porous network, represent another breakthrough in biomolecule chromatography. Their high permeability and convective mass transfer properties enable rapid

separations with minimal backpressure. Monolithic silica and polymeric supports have shown remarkable efficiency in separating large biomolecules such as immunoglobulins, viral particles, and protein complexes [14]. Recent developments in 3D-printed and functionalized monoliths have expanded their customizability for specific biopharmaceutical applications. Collectively, these advancements in column chemistry have ushered in an era of ultra-fast, high-resolution separations tailored to the physicochemical complexity of modern biologics [15].

1.3 Optimization of Mobile Phases and Solvent Systems for Complex Biologics

Mobile-phase design is pivotal in dictating selectivity, peak symmetry, and recovery of sensitive biomolecules. For peptide and protein separations, volatile buffers such as formic acid and ammonium acetate are preferred due to their compatibility with mass spectrometric detection. Organic modifiers like acetonitrile and methanol are widely used, though temperature and pH adjustments can drastically alter retention behavior and conformational stability [16]. Recent innovations include the use of ionic liquids, fluorinated solvents, and mixed aqueous–organic systems that enhance solubility and minimize adsorption losses.

Gradient elution remains the mainstay for resolving complex biological mixtures, yet the introduction of temperature-programmed HPLC (thermally assisted chromatography) has enabled modulation of protein hydrophobicity and secondary structure during analysis. Moreover, buffer-free and low-salt methods are being developed to support environmentally sustainable and MS-compatible workflows [17]. For oligonucleotide analysis, triethylamine–hexafluoroisopropanol (TEA–HFIP) systems remain dominant, though emerging alternatives such as alkylamine acetate buffers offer lower toxicity and improved ionization efficiency [18]. Optimization strategies are increasingly guided by chemometric tools and AI-based modeling that predict retention behavior and gradient outcomes. Machine learning algorithms now assist in fine-tuning solvent ratios, flow rates, and column temperatures, yielding faster method development cycles and greater reproducibility [19]. Thus, the evolution of mobile-phase formulation reflects the broader digital transformation of HPLC balancing physicochemical optimization with sustainability and computational intelligence.

1.4 High-Resolution and Ultra-High-Pressure HPLC (UHPLC) Platforms

The transition from conventional HPLC to ultra-high-performance liquid chromatography (UHPLC) represents one of the most significant technological milestones in analytical science. By operating at pressures exceeding 15,000 psi, UHPLC allows the use of sub-2 μm particles, achieving exceptional separation efficiency within shorter run times [20]. This innovation has been instrumental in the high-throughput analysis of biopharmaceutical products, where sample complexity and batch volumes necessitate rapid yet precise quantitation. UHPLC columns, often packed with superficially porous or hybrid particles, deliver improved resolution for peptides, oligonucleotides, and glycoproteins. Additionally, enhanced thermal control and microfluidic optimization mitigate on-column degradation and band broadening, which are critical when handling labile biomolecules. The use of specialized instruments with reduced system dwell volumes and advanced pump designs further ensures reproducibility at ultra-high pressures [21].

The integration of UHPLC with tandem mass spectrometry (UHPLC–MS/MS) has enabled unparalleled structural elucidation and impurity profiling. Its superior signal-to-noise ratio, coupled with high peak capacity, allows detailed mapping of post-translational modifications and product-related variants. Importantly, UHPLC also supports miniaturized, chip-based systems compatible with microfluidic bioprocessing platforms. These compact designs align with the growing trend toward continuous manufacturing and in-line analytical monitoring in biopharmaceutical production [22].

1.5 Advances in Detection Techniques Coupled with HPLC

Detection systems are the analytical eyes of chromatography, transforming molecular separations into quantifiable data. The evolution from simple UV detectors to multi-dimensional arrays and mass spectrometers has dramatically expanded the analytical scope of HPLC. Diode-array detection (DAD) remains essential for multi-wavelength spectral acquisition, facilitating purity assessments and peak identification. Fluorescence detection (FLD) offers superior sensitivity for analytes with intrinsic or derivatized chromophores, particularly in peptide and protein assays [23].

Evaporative light scattering detection (ELSD) and charged aerosol detection (CAD) have proven indispensable for non-UV absorbing analytes such as carbohydrates, lipids, and glycoproteins. For biomolecule quantification, especially in formulations and biosimilars, CAD provides enhanced reproducibility and mass sensitivity independent of analyte optical properties. The coupling of HPLC with mass spectrometry (LC–MS/MS) represents the apex of detection capability, enabling molecular weight confirmation, sequence verification, and impurity tracking at femtomolar sensitivity [24]. Recent innovations include time-of-flight (TOF) and Orbitrap-based high-resolution MS systems, which allow simultaneous qualitative and quantitative characterization of complex mixtures. Advanced data deconvolution algorithms now process massive datasets to distinguish co-eluting species and detect minor modifications. Collectively, these detector enhancements have

elevated HPLC from a separation tool to an integrated analytical powerhouse capable of decoding biopharmaceutical complexity with precision and speed [25].

1.6 Automation and AI-Driven Chromatographic Workflows

The integration of automation and artificial intelligence (AI) into chromatographic systems has redefined analytical efficiency in modern biopharmaceutical laboratories. Automation encompasses robotic autosamplers, online sample preparation, gradient optimization, and unattended overnight runs, which collectively minimize operator variability and enhance reproducibility [26]. In biopharmaceutical quality control (QC) environments, automated sample injection and fraction collection systems enable high-throughput testing of complex protein and peptide formulations, thereby improving process efficiency and reducing turnaround time. Artificial intelligence and machine learning (ML) have further transformed chromatographic workflows by providing predictive and adaptive analytical intelligence. Algorithms trained on historical chromatographic datasets can predict retention times, optimize gradient profiles, and detect anomalies such as baseline drift, ghost peaks, or co-eluting impurities. Automated peak deconvolution and retention modeling using neural networks or support vector machines have accelerated method development and ensured consistent analytical quality [27]. AI-driven chromatographic software such as Empower™ and Chromeleon™ now integrate real-time feedback loops that adjust flow rates or gradient slopes dynamically during runs to maintain target resolutions.

Beyond operational automation, the fusion of AI with chemometrics has revolutionized data interpretation and decision-making. Principal component analysis (PCA) and partial least squares (PLS) regression models assist in identifying subtle variations in chromatographic fingerprints, supporting comparability studies for biosimilars and process validation [28]. The deployment of robotics in parallel with AI-based scheduling further enables seamless analytical sequencing, reducing manual intervention and improving safety in high-containment biologics laboratories. These developments are pivotal for the evolution of "smart chromatography," wherein intelligent algorithms govern analytical precision, data integrity, and decision-making across the biopharmaceutical value chain [29].

1.7 Quality-by-Design (QbD) and Method Robustness in HPLC Development

The implementation of Quality-by-Design (QbD) principles in HPLC method development represents a paradigm shift from empirical testing to systematic analytical design. In alignment with ICH Q8–Q11 guidelines, QbD emphasizes scientific understanding and control of chromatographic processes through predefined design spaces and critical quality attributes (CQAs) [30]. A well-structured QbD approach begins with identifying analytical target profiles (ATPs), followed by the determination of critical method parameters (CMPs) such as pH, mobile-phase composition, gradient slope, and temperature. These are then statistically optimized using Design of Experiments (DoE) methodologies. Recent advancements in computational modeling and simulation software enable the creation of predictive design spaces that visualize robustness and failure regions in multidimensional parameter landscapes [31]. For instance, chromatographic modeling platforms such as DryLab® or ChromSword® facilitate virtual experiments that reduce experimental workload by 50–70%. These digital tools also allow prediction of retention behavior and selectivity under varying conditions, which is crucial for peptide and oligonucleotide separations where small parameter shifts can induce significant selectivity changes.

QbD-driven chromatographic methods inherently possess greater robustness, ensuring consistent performance across batches and instruments. Lifecycle management, a key component of QbD, extends this robustness through continuous monitoring, revalidation, and knowledge transfer across analytical sites. Regulatory agencies such as the U.S. FDA, EMA, and PMDA now expect chromatographic methods supporting biologics license applications (BLAs) to demonstrate QbD-based design and risk mitigation strategies [32]. Thus, integrating QbD within HPLC development not only ensures regulatory compliance but also fosters a culture of scientific control, predictive reliability, and continuous improvement in analytical performance [33].

1.8 Data Integrity, Digital Chromatography, and Cloud-Based Systems

Data integrity has become a cornerstone of modern biopharmaceutical analytics, particularly under the scrutiny of global regulatory frameworks such as FDA 21 CFR Part 11, EU Annex 11, and WHO GxP guidelines. Digital chromatography embodies the transformation of traditional HPLC systems into fully networked, compliant, and traceable analytical ecosystems [34]. Electronic laboratory notebooks (ELNs) and laboratory information management systems (LIMS) now integrate directly with HPLC software, enabling seamless acquisition, storage, and audit trails of chromatographic data. Cloud-based systems further enhance scalability, accessibility, and cybersecurity by centralizing chromatographic records and analytical metadata. These platforms enable global collaboration and real-time oversight of analytical operations across manufacturing sites. Blockchain-inspired digital ledgers have also been proposed for securing chromatographic datasets against tampering, thereby reinforcing traceability and compliance [35]. AI-assisted algorithms embedded within these systems can continuously monitor analytical trends, flag deviations, and recommend corrective actions, supporting continuous verification models in pharmaceutical manufacturing.

Furthermore, the integration of Internet of Things (IoT) sensors with chromatographic instruments facilitates remote condition monitoring tracking column pressure, solvent levels, and detector performance in real time. Such connectivity allows predictive maintenance and minimizes instrument downtime, aligning with the broader objectives of Industry 4.0 and 5.0 digital manufacturing ecosystems [36]. As biopharmaceutical data volumes grow exponentially, the evolution toward digital chromatography ensures data integrity, reproducibility, and regulatory readiness, positioning HPLC as both an analytical and informatic cornerstone of future-ready bioprocess laboratories [37].

1.9 Green and Sustainable HPLC Practices in Biopharma

Sustainability has emerged as an essential parameter in the evolution of HPLC methodology, addressing both environmental and economic imperatives. The conventional use of organic solvents such as acetonitrile, methanol, and tetrahydrofuran presents significant ecological challenges due to their toxicity and disposal requirements. Consequently, green HPLC practices emphasize solvent reduction, waste minimization, and energy-efficient operation without compromising analytical performance [38]. The development of micro- and nano-scale HPLC systems has substantially reduced solvent consumption by miniaturizing column and tubing dimensions. Sub-microliter flow systems, including capillary and nano-HPLC, now achieve equivalent or superior resolution to conventional systems while consuming less than one-tenth of the solvent volume [39]. The replacement of toxic solvents with greener alternatives, such as ethanol, propylene carbonate, or ionic liquid-based mobile phases, has gained momentum in peptide and oligonucleotide analysis. Additionally, aqueous normal-phase (ANP) and supercritical fluid chromatography (SFC) are being explored as eco-friendly alternatives that reduce organic waste generation.

Column recyclability and longer column lifetimes through hybrid material use also contribute to sustainability. Temperature-controlled separations minimize energy usage, and advances in pump design have reduced solvent leakage and operational noise. Furthermore, automated solvent recovery systems now enable the recycling of acetonitrile and methanol for repeated analytical runs. As the biopharmaceutical industry advances toward carbon-neutral manufacturing, green chromatography will remain central to achieving environmentally responsible analytical operations [40]. The confluence of sustainability with analytical innovation not only enhances laboratory safety and efficiency but also fulfills the broader ethical commitment of the pharmaceutical industry toward sustainable development [41].

1.10 Integration of HPLC with Orthogonal Analytical Techniques

The intrinsic complexity of biopharmaceutical products often necessitates multi-dimensional analytical approaches that extend beyond single chromatographic measurements. The integration of HPLC with orthogonal analytical techniques such as capillary electrophoresis (CE), mass spectrometry (MS), nuclear magnetic resonance (NMR), and infrared spectroscopy (IR) has become the standard for comprehensive molecular characterization [42]. These hybrid analytical workflows exploit the complementary strengths of each method, yielding enhanced structural, physicochemical, and functional insights. LC–MS remains the most powerful of these integrations, offering molecular weight confirmation, sequence mapping, glycan profiling, and degradation analysis with unparalleled precision. For large biomolecules, LC coupled with ion mobility spectrometry (LC–IMS–MS) provides conformational and structural data essential for understanding folding and stability. The combination of HPLC and CE has also proven invaluable in charge variant analysis and capillary-based peptide mapping, where high-resolution separation of isoforms is critical [43]. Moreover, the integration of HPLC with spectroscopic detectors such as fluorescence, Raman, or circular dichroism enables simultaneous acquisition of structural and functional data. In the context of biosimilar development, orthogonal HPLC methods play a crucial role in demonstrating analytical comparability. Combining reversed-phase HPLC for purity with SEC for aggregation and IEX for charge variants forms the triad of analytical assurance that supports regulatory submissions. Emerging workflows now incorporate two-dimensional liquid chromatography (2D-LC), where multiple separation mechanisms are coupled in a single system, further enhancing selectivity and throughput [44]. The future lies in fully automated, multi-modal analytical platforms that integrate HPLC, CE, MS, and spectroscopic modules under unified digital control. Such systems will provide holistic biopharmaceutical characterization, reducing redundancy and accelerating regulatory acceptance [45].

1.11 Emerging Trends in Peptide and Oligonucleotide Analysis

Peptide- and oligonucleotide-based therapeutics have become integral to the modern biopharmaceutical landscape, driving innovation in analytical chromatography. These biomolecules present unique analytical challenges due to their amphiphilic nature, structural heterogeneity, and sensitivity to pH and temperature variations. HPLC has evolved to address these complexities through novel stationary phases, enhanced detection modalities, and AI-assisted data interpretation [46]. In peptide analysis, reversed-phase HPLC (RP-HPLC) remains the gold standard, utilizing C18 or phenyl-hexyl columns optimized for hydrophobic interaction. Recent trends emphasize the use of core–shell and hybrid particle columns, which offer enhanced mass transfer and

improved resolution for closely related peptide variants. Gradient elution under controlled temperature (up to 80°C) enhances separation of co-eluting isoforms and truncated species. Additionally, two-dimensional HPLC (2D-HPLC), combining reversed-phase with ion-exchange or hydrophilic interaction chromatography, is now widely employed for mapping post-translational modifications (PTMs) such as glycosylation, acetylation, and phosphorylation [47].

Oligonucleotide chromatography has witnessed parallel advancements, primarily through ion-pair reversed-phase (IP-RP) and anion-exchange (AEX) HPLC techniques. The use of volatile ion-pairing agents, including triethylamine and hexafluoroisopropanol (TEA–HFIP), enables direct coupling with mass spectrometry for sequence confirmation and impurity profiling. However, environmental and safety concerns have prompted the development of low-toxicity alternatives such as dimethylbutylamine (DMBA) or alkylammonium acetate buffers [48]. Additionally, hybrid particle columns with extended pore sizes (300 Å) have been designed to accommodate large oligonucleotides and RNA constructs, ensuring reduced on-column shearing and improved recovery. Another emerging dimension is the integration of computational tools and AI models for predictive peptide and oligonucleotide retention modeling. These systems utilize molecular descriptors, sequence hydrophobicity, and structural motifs to simulate chromatographic behavior and guide method development [49]. Advanced software now performs retention time alignment, spectral deconvolution, and sequence annotation with minimal manual intervention. Collectively, these trends underline the centrality of HPLC in enabling robust, high-resolution, and regulatory-compliant characterization of next-generation peptide and oligonucleotide drugs, particularly as these modalities advance toward mRNA vaccines, antisense therapies, and peptide–drug conjugates [50].

1.12 Application of HPLC in Process Analytical Technology (PAT)

Process Analytical Technology (PAT), as defined by the U.S. FDA, emphasizes real-time monitoring and control of manufacturing processes to ensure consistent product quality. HPLC, with its unparalleled selectivity and quantitative accuracy, has become a core analytical pillar within PAT frameworks for biopharmaceutical production. Traditionally regarded as an off-line analytical tool, HPLC is now being re-engineered for in-line and at-line applications through miniaturization, automation, and integration with feedback-controlled bioprocessing systems [51]. At-line HPLC enables sampling at critical manufacturing stages such as fermentation, purification, and formulation, providing rapid feedback on process variables. Recent innovations in microfluidic HPLC modules have enabled true in-line operation, allowing real-time analysis of critical quality attributes (CQAs) such as purity, aggregation, and residual host-cell proteins. These data streams feed directly into control algorithms that adjust process parameters in real time, ensuring batch consistency [52].

Furthermore, the coupling of HPLC with advanced detectors, particularly mass spectrometry and fluorescence, enhances PAT's capacity to track low-abundance impurities and degradation products. The use of rapid-gradient UHPLC platforms has drastically reduced analysis time, allowing near-continuous monitoring without interrupting the production cycle. Integration with chemometric modeling and AI enables multivariate process control identifying correlations between chromatographic data and upstream parameters like temperature, pH, and feed rate [53]. HPLC-based PAT strategies are now central to continuous manufacturing paradigms, wherein production and quality assurance occur concurrently. Regulatory authorities increasingly advocate for such systems, citing improved reproducibility, reduced waste, and enhanced traceability. The evolution of HPLC from an analytical endpoint test to an embedded process-monitoring tool marks a critical milestone in the realization of digital biomanufacturing and Quality 4.0 in the pharmaceutical industry [54].

Table 1: Comparative Overview of Advanced Column Technologies for Biopharmaceutical HPLC

Column Type	Particle Composition	Typical Pore Size(Å)	Key Advantages	Limitations	Representative Applications in Biopharma	Recent References
Fully Porous Silica (FPP)	Silica or modified silica	100–300	Widely available; high surface area; compatible with multiple modes	Lower efficiency at high flow; diffusion limitations	Routine peptide and small protein separations	[11], [16]
Superficially Porous Particles (SPP)	Solid core with porous shell	90–160	Reduced eddy diffusion; faster mass transfer; high efficiency under moderate pressure	Limited loading capacity for large biomolecules	Peptide mapping, impurity profiling, biosimilar comparability	[12], [13]

Hybrid Organic–Silica	Organically bridged silica (BEH, CSH)	130–300	Enhanced pH stability; longer column life; minimal silanol activity	Higher cost; specialized hardware	Oligonucleotide and peptide separations at extreme pH	[13], [19]
Polymeric Columns	Polystyrene–divinylbenzene or polymethacrylate	300–1000	Suitable for large biomolecules and harsh solvents; reusable	Broader peak widths; limited resolution for small analytes	Size-exclusion and affinity chromatography of antibodies	[14], [39]
Monolithic Columns	Continuous silica or polymer network	1000–2000	High permeability; low backpressure; ideal for macromolecules	Limited availability; lower theoretical plates	High-throughput protein and viral vector separations	[15], [40]

Table 2: Integration of Automation, AI, and Digital Platforms in Modern Biopharmaceutical HPLC Workflows

Analytical Domain	Technological Advancement	Functional Impact	Analytical Benefits	Key References
Sample Preparation	Robotic autosamplers and liquid handlers	Automated sample injection, dilution, and filtration	Reduced human error; improved reproducibility	[26], [29]
Chromatographic Optimization	AI/ML-based gradient prediction and retention modeling	Predicts optimal flow, solvent composition, and gradient	Faster method development; lower solvent consumption	[27], [31]
Data Processing	Neural-network-assisted peak identification	Automated deconvolution of co-eluting species	Increased accuracy in purity profiling	[28], [61]
Regulatory Compliance	Cloud-integrated ELNs and LIMS	Centralized data storage, version tracking	Enhanced data integrity, audit readiness	[34], [35]
Predictive Maintenance	IoT-enabled condition monitoring	Real-time hardware diagnostics	Reduced downtime; extended instrument lifespan	[36], [63]
Digital Twin Simulation	Virtual replica of chromatographic systems	Real-time optimization and scenario modeling	Continuous process improvement	[57], [64]



Fig 1: Evolution of HPLC Column Chemistry for Biopharmaceutical Analysis



Fig 2: Digital Transformation of HPLC in Biopharmaceutical Workflows

1.13 Future of HPLC in Biopharma: From Batch to Continuous Analytics

The biopharmaceutical industry is transitioning from conventional batch processing toward continuous and adaptive manufacturing, and HPLC stands at the forefront of this transformation. Continuous analytics entails real-time data generation and interpretation across all manufacturing stages facilitated by HPLC systems capable of autonomous operation, self-calibration, and predictive control [55]. Microfluidic and chip-based HPLC systems are revolutionizing analytical workflows by miniaturizing components, reducing solvent use, and enabling seamless integration with continuous reactors and purification modules. These "lab-on-a-chip" systems deliver high-frequency data suitable for real-time release testing (RTRT), allowing immediate product disposition decisions based on in-process analytical results [56]. The integration of HPLC within closed-loop control systems ensures dynamic adjustment of parameters such as flow rate, temperature, and mobile-phase gradient to maintain optimal performance. AI-enhanced continuous HPLC systems are capable of real-time data interpretation, anomaly detection, and self-correction. Digital twins virtual replicas of chromatographic processes simulate real-world system behavior and predict performance under varying operational conditions. This approach allows proactive maintenance, reduced downtime, and improved analytical precision [57]. Furthermore, cloud-connected continuous HPLC platforms support remote supervision and regulatory traceability, enabling globally harmonized manufacturing environments. The transition toward continuous analytics also aligns with sustainability and efficiency goals. Reduced solvent consumption, minimized sample preparation, and shorter analysis cycles collectively decrease environmental impact and cost. As the industry embraces Industry 5.0 paradigms where human expertise and machine intelligence co-evolve HPLC will remain a critical enabler of data-rich, autonomous, and sustainable biopharmaceutical manufacturing [58].

1.14 Challenges and Limitations in Modern HPLC Systems

Despite its unparalleled utility, modern HPLC faces several challenges that constrain its universal application across biopharmaceutical modalities. The high operational cost of UHPLC systems, coupled with stringent maintenance requirements, can limit accessibility for smaller laboratories. The complexity of biologics often leads to column fouling, carryover, and limited column lifetimes, particularly when analyzing proteins with high aggregation or binding tendencies [59]. Another persistent challenge lies in sample preparation. Biopharmaceutical matrices comprising buffers, excipients, and cellular residues often necessitate extensive pre-treatment steps such as filtration, dilution, or enzymatic digestion, which introduce variability and analytical delays. Furthermore, the incompatibility of certain biological samples with traditional mobile-phase solvents can lead to denaturation or precipitation of biomolecules [60].

Data overload represents a new-age bottleneck in chromatographic science. As multi-dimensional HPLC systems generate vast datasets, manual interpretation becomes impractical. Although AI and chemometrics provide solutions, their implementation requires significant computational resources and expertise. Regulatory compliance also poses challenges, especially in maintaining audit trails, data integrity, and electronic validation within globally distributed analytical networks [61]. Instrumental limitations, including pump pulsation, detector linearity, and column-to-column variability, remain significant hurdles for ultra-trace quantification. Moreover, interlaboratory reproducibility issues persist due to subtle differences in system configuration and operator proficiency. Addressing these challenges demands holistic strategies encompassing hardware innovation, operator training, digital harmonization, and cross-industry standardization [62]. As biopharmaceutical analysis grows increasingly data-driven, overcoming these limitations will be essential to maintain HPLC's central role in analytical excellence.

1.15 Future Perspectives and Conclusion

The evolution of HPLC in the biopharmaceutical era reflects the convergence of analytical chemistry, materials science, automation, and data intelligence. The next generation of HPLC systems will transcend their traditional boundaries to become autonomous, predictive, and fully integrated within digital manufacturing ecosystems. The incorporation of AI-driven optimization, digital twins, and blockchain-based data traceability will transform HPLC into a cornerstone of Industry 5.0-ready biopharma analytics [63]. Advances in column materials including bioinert hybrid phases, nanoporous composites, and 3D-printed monoliths will continue to enhance separation efficiency and stability for complex biomolecules. Concurrently, green chromatography initiatives will minimize environmental footprints through solvent recycling, low-energy operation, and eco-compatible stationary phases. Integration with orthogonal analytical technologies, such as CE, NMR, and MS, will yield multi-parametric data capable of decoding molecular heterogeneity at unprecedented resolution [64].

Furthermore, HPLC will increasingly contribute to personalized and precision biomanufacturing by enabling rapid release testing, real-time product monitoring, and predictive quality modeling. AI-assisted method development will drastically reduce analytical timelines, while digital data ecosystems will ensure global standardization and regulatory alignment. However, achieving this vision demands collaborative innovation across academia, industry, and regulatory bodies, ensuring interoperability and ethical data stewardship [65]. In conclusion, HPLC remains an indispensable analytical tool in the biopharmaceutical era constantly reinventing itself through material, mechanical, and digital innovations. Its transformation from a laboratory-based assay to an intelligent, networked analytical platform symbolizes the broader evolution of pharmaceutical science itself: from reactive analysis toward proactive, autonomous quality assurance. As the biopharma industry advances into the era of continuous manufacturing, sustainability, and data-centric innovation, HPLC will continue to illuminate the molecular intricacies that define the medicines of tomorrow.

REFERENCES

1. Nováková L, et al. Recent trends in HPLC analysis of biopharmaceuticals. *J Chromatogr A.* 2019;1602:1–24.
2. Vailaya A, Horváth C. Modern developments in HPLC stationary phases for biomolecules. *Anal Chem.* 2020;92(14):9400–9414.
3. Rathore AS, et al. Quality by design for biopharmaceuticals: Analytical perspectives. *Trends Biotechnol.* 2021;39(5):503–516.
4. Sarrut M, Heinisch S. Theoretical and practical aspects of HPLC in complex biopharmaceutical matrices. *J Sep Sci.* 2020;43(2):310–329.
5. Dong MW. *Modern HPLC for Practicing Scientists.* 3rd ed. Wiley; 2023.
6. Li W, et al. HPLC in the characterization of monoclonal antibodies and biosimilars. *J Pharm Biomed Anal.* 2020;189:113451.
7. Szabo Z, et al. Peptide mapping using UHPLC–MS: A review. *Anal Bioanal Chem.* 2021;413(6):1389–1410.

8. Kumar S, et al. Oligonucleotide analysis using HPLC–MS: Emerging trends and challenges. *J Chromatogr B.* 2022;1190:123089.
9. Liu YD, et al. Analytical comparability in biosimilar development: Role of HPLC. *MAbs.* 2021;13(1):1882145.
10. FDA. *Analytical Procedures and Methods Validation for Drugs and Biologics.* Guidance for Industry. 2022.
11. Gritti F, Guiochon G. Superficially porous particles in HPLC. *J Chromatogr A.* 2019;1605:360–377.
12. Broeckhoven K, Desmet G. Advances in superficially porous particle technology. *Anal Chem.* 2020;92(17):11438–11449.
13. Olesik SV. Hybrid stationary phases for robust biopharmaceutical separations. *TrAC Trends Anal Chem.* 2021;143:116374.
14. Urban J. Monolithic columns in modern chromatography. *J Chromatogr A.* 2020;1625:461237.
15. Cabrera K. Monolithic supports in HPLC: Evolution and applications. *LCGC North Am.* 2022;40(8):474–485.
16. Buszewski B, et al. Mobile phase optimization in peptide separations. *J Sep Sci.* 2021;44(12):2437–2450.
17. Wrona M, et al. Ionic liquids and fluorinated solvents in biopharmaceutical HPLC. *J Chromatogr A.* 2022;1675:463114.
18. McGinnis AC, et al. Optimization of TEA–HFIP systems in oligonucleotide analysis. *Anal Bioanal Chem.* 2021;413(12):3183–3194.
19. Singh P, et al. AI-assisted HPLC method development in peptide analytics. *Anal Chim Acta.* 2023;1258:341312.
20. Nguyen DTT, et al. UHPLC for biomolecule analysis: A decade of innovation. *J Chromatogr A.* 2020;1610:460579.
21. Dolan JW. UHPLC performance and validation in QC laboratories. *LCGC Europe.* 2021;34(9):520–531.
22. Roca LS, et al. Integration of UHPLC with microfluidic systems. *Anal Methods.* 2022;14(8):923–937.
23. Bobaly B, et al. Advances in HPLC detection for complex biopharmaceuticals. *J Pharm Biomed Anal.* 2023;229:115451.
24. Wang T, et al. Quantitative HPLC–MS analysis of therapeutic proteins. *Anal Chem.* 2021;93(18):6981–6994.
25. Gao X, et al. Orbitrap and TOF-MS in advanced HPLC applications. *Mass Spectrom Rev.* 2023;42(4):1020–1045.
26. Bevan C, et al. Robotics and automation in liquid chromatography. *Lab Chip.* 2020;20(15):2752–2763.
27. Sharma N, et al. Machine learning applications in chromatographic optimization. *J Chemom.* 2022;36(3):e3412.
28. Rajamani S, et al. Chemometric modeling for HPLC fingerprint analysis in biopharma. *Anal Bioanal Chem.* 2021;413(10):2571–2585.
29. Zhu X, et al. Smart chromatography: AI in automated analytics. *Analyst.* 2023;148(5):1274–1287.
30. ICH Harmonised Guideline Q8–Q11. Pharmaceutical Development. ICH; 2019.
31. Vervoort N, et al. Design of Experiments in HPLC method development. *J Chromatogr B.* 2020;1158:122345.
32. Rathore AS. Implementation of QbD in analytical methods for biopharmaceuticals. *Pharm Technol.* 2021;45(2):36–44.
33. Szabo P, et al. Lifecycle management of analytical methods in biopharma. *TrAC Trends Anal Chem.* 2022;149:116553.
34. European Medicines Agency (EMA). *Data Integrity Requirements for Analytical Laboratories.* 2021.
35. Altuve A, et al. Blockchain applications in analytical data integrity. *Comput Struct Biotechnol J.* 2022;20:5372–5384.
36. Chen Q, et al. IoT-enabled smart chromatography for predictive maintenance. *Sensors.* 2023;23(4):2268.
37. Sanderson K. Digital transformation of analytical laboratories. *Nat Biotechnol.* 2021;39(10):1245–1253.
38. Tobiszewski M, et al. Green chemistry metrics in HPLC. *Green Chem.* 2020;22(3):758–772.
39. Moravcova D, et al. Capillary and nano-HPLC for sustainable biopharmaceutical analysis. *J Chromatogr A.* 2022;1677:463241.
40. Armenta S, et al. Greening analytical chemistry. *TrAC Trends Anal Chem.* 2021;142:116327.
41. Koel M, et al. Eco-friendly solvents in pharmaceutical analysis. *Anal Bioanal Chem.* 2020;412(12):2841–2852.
42. Nováková L, et al. Orthogonal analytical methods in biopharmaceutical characterization. *J Pharm Biomed Anal.* 2020;187:113312.
43. Fekete S, et al. 2D-LC and CE–MS for charge variant analysis. *J Chromatogr A.* 2021;1648:462175.
44. Yan X, et al. Two-dimensional LC–MS in biopharma analytics. *Anal Chim Acta.* 2023;1265:341473.
45. Mattila S, et al. Integrated multi-modal analytics for biologics. *Analyst.* 2022;147(9):1881–1894.

46. Quirke J, et al. Peptide analytics by reversed-phase and 2D-HPLC. *J Chromatogr B.* 2021;1188:123067.
47. Kishimoto S, et al. Mapping peptide PTMs by multidimensional chromatography. *Anal Chem.* 2022;94(12):4735–4748.
48. Dillen L, et al. Advances in oligonucleotide chromatography. *J Chromatogr A.* 2023;1701:464101.
49. Takahashi Y, et al. Computational retention modeling for peptide chromatography. *J Chem Inf Model.* 2021;61(9):4352–4364.
50. Wang Q, et al. Chromatographic strategies for RNA-based therapeutics. *Anal Bioanal Chem.* 2022;414(9):2791–2805.
51. Vetter T, et al. Real-time HPLC in PAT frameworks. *Biotechnol Prog.* 2021;37(4):e3102.
52. Yoon J, et al. Microfluidic HPLC integration for in-line monitoring. *Lab Chip.* 2022;22(5):865–878.
53. Rathore AS, et al. Chemometrics in process analytical technology. *TrAC Trends Anal Chem.* 2020;132:116046.
54. FDA. *Guidance for Industry: PAT A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance.* 2021.
55. Wong J, et al. Continuous biomanufacturing and chromatographic analytics. *Biotechnol Adv.* 2022;54:107871.
56. Kostiainen R, et al. Microfluidic HPLC in continuous systems. *Anal Methods.* 2021;13(11):1335–1347.
57. Rani S, et al. Digital twins for continuous chromatography. *Comput Chem Eng.* 2023;179:108365.
58. Wang Y, et al. AI-driven real-time release testing in continuous bioprocessing. J Pharm Innov. 2024;19(2):311–325.
59. Li H, et al. Column fouling and recovery strategies in biopharmaceutical HPLC. J Chromatogr A. 2021;1643:462071.
60. Anderson C, et al. Challenges in sample preparation for biologics analysis. Anal Bioanal Chem. 2020;412(17):4279–4292.
61. Zhang L, et al. Data overload and AI interpretation in HPLC. Analyst. 2023;148(7):1961–1975.
62. Jenkins K, et al. Reproducibility challenges in interlaboratory HPLC studies. J Pharm Biomed Anal. 2022;214:114654.
63. Xu Z, et al. Blockchain, AI, and digital twins in analytical sciences. TrAC Trends Anal Chem. 2023;155:117061.
64. Buszewski B, et al. Hybrid stationary phases and green solvents in advanced HPLC. J Sep Sci. 2023;46(5):1289–1310.
65. Rocco A, et al. The roadmap to autonomous chromatography. Anal Chim Acta. 2024;1273:341882.